Medtronic PLC $MDT Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. lowered its stake in Medtronic PLC (NYSE:MDT) by 10.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,794 shares of the medical technology company’s stock after selling 8,172 shares during the quarter. Meyer Handelman Co.’s holdings in Medtronic were worth $6,512,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of MDT. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the second quarter worth $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the third quarter valued at $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the third quarter valued at $29,000. Board of the Pension Protection Fund purchased a new stake in Medtronic during the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC purchased a new stake in Medtronic during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the topic of a number of recent research reports. CICC Research began coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. lowered their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Leerink Partners reissued an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. Finally, Robert W. Baird decreased their target price on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Up 1.0%

Shares of NYSE:MDT opened at $86.57 on Wednesday. The stock’s 50-day moving average price is $95.34 and its two-hundred day moving average price is $96.41. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a market cap of $111.15 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.21 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio is 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).